Lixte Biotechnology Holdings, Inc. Share Price
LIXT
$4.08
-$0.28 (-6.42%) Last updated on 02 Sep, 2025 | 23:38 ISTLixte Biotechnology Holdings, Inc. Stock Performance
Open $4.23 | Prev. Close $4.36 | Circuit Range N/A |
Day Range $4.09 - $4.23 | Year Range $0.64 - $5.03 | Volume 500 |
Average Traded $4.13 |
Lixte Biotechnology Holdings, Inc. Share Price Chart
$4.08
About Lixte Biotechnology Holdings, Inc.
Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company's LB-100 combined with doxorubicin in advanced soft tissue sarcoma is under Phase 1b portion; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.
Lixte Biotechnology Holdings, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
29-Aug-25 | $3.99 | $4.36 | +11.79% |
28-Aug-25 | $3.47 | $3.90 | +11.43% |
26-Aug-25 | $3.23 | $3.50 | +7.03% |
25-Aug-25 | $3.45 | $3.27 | -4.66% |
22-Aug-25 | $3.46 | $3.43 | +0.59% |
21-Aug-25 | $3.46 | $3.41 | +0.00% |
19-Aug-25 | $3.77 | $3.41 | -10.50% |
FAQs on Lixte Biotechnology Holdings, Inc. Share Price
Can I buy Lixte Biotechnology Holdings, Inc. shares in India?
What is the share price of Lixte Biotechnology Holdings, Inc.?
What is the 5 year returns of Lixte Biotechnology Holdings, Inc.?
What are the high & low stock price of Lixte Biotechnology Holdings, Inc. today?
What is the 52-week high and low of Lixte Biotechnology Holdings, Inc. stock?